Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing
PLOS Computational Biology · 17.11.2026 · 22 (11) · e1014828
DOI: 10.1371/journal.pcbi.1014828 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 17.11.2026. Verfasst von Jifeng Miao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spinal Bone Diseases Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Osteosarcoma, Osteolysis, Bone Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangxi Province, Guangxi Key Research and Development Program, Youth Science Foundation of Guangxi Medical University.
Abstract (Originalsprache)
Osteosarcoma-associated osteolysis represents a major obstacle in the management of osteosarcoma. Within the osteolytic microenvironment, interactions between osteoclasts and tumor cells facilitate tumor proliferation and metastatic dissemination, and contribute to the development of pathological fractures. However, conventional osteoclast-targeting agents are insufficient to effectively suppress osteosarcoma-driven bone resorption. In this study, single-cell RNA sequencing was performed to identify critical regulators involved in osteoclast differentiation in the context of osteosarcoma. Using the Beyondcell platform, drugs targeting osteoclast-related signaling pathways were screened, and oxfendazole (OFN) was identified as a potential therapeutic candidate, with ANXA2 recognized as a key associated target. In vitro osteoclastogenesis assays and an in vivo tibial orthotopic osteosarcoma model demonstrated that oral administration of OFN via gavage effectively suppressed osteoclast formation and osteolytic activity, as confirmed by micro-CT and histopathological analyses. But OFN alone did not significantly inhibit osteosarcoma growth but effectively reduced osteoclast-mediated osteolysis. In addition, qRT-PCR and immunohistochemistry confirmed that OFN downregulates ANXA2 expression in vitro and in vivo, thereby impairing osteoclast differentiation. Molecular dynamics simulations combined with in-vitro validation further suggested that OFN may interact with the transcription factor ZNF530, leading to reduced ANXA2 transcription. In conclusion, the integration of single-cell RNA sequencing with the Beyondcell algorithm enabled the identification of OFN as a potent candidate agent for osteosarcoma-induced osteolysis. OFN attenuates osteoclastogenesis and bone resorption by suppressing ANXA2 expression. These findings provide preclinical evidence supporting the therapeutic potential of OFN in the treatment of osteosarcoma-associated osteolysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Spinal Bone Diseases Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Bone and Joint Diseases Surger, Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Spinal Surgery, 923RD Hospital of PLA, Nanning, China.
- Department of Spinal Surgery, The People's Hospital of Chongzuo, Chongzuo, China.
- Department of Bone and Soft Tissue Tumor Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
ORCID-Profile: Yun Liu, Qingjun Wei
Förderung
- Natural Science Foundation of Guangxi Province
- Guangxi Key Research and Development Program
- Youth Science Foundation of Guangxi Medical University
- Self-funded Research Project of Guangxi Health Commission
- National Natural Science Foundation of China
- Cultivation Science Foundation of The Second Affiliated Hospital of Guangxi Medical University
- Guangxi Green Seedling Talent Inclusive Support Policy
- Open Project of Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical Universit
Zitieren
APA
Miao, J., Wang, P., Feng, W., Quan, H., Lin, Y., Wei, G., Meng, F., Li, S., Yang, M., Ning, B., Deng, J., Xiong, L., Hu, J., Liu, Y., & Wei, Q. (2026). Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing. PLOS Computational Biology, 22(11), e1014828. https://doi.org/10.1371/journal.pcbi.1014828
Vancouver
Miao J, Wang P, Feng W, Quan H, Lin Y, Wei G, et al. Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing. PLOS Computational Biology. 2026;22(11):e1014828. doi:10.1371/journal.pcbi.1014828
BibTeX
@article{Miao2026,
author = {Miao, Jifeng and Wang, Pintian and Feng, Wenyu and Quan, Haiyi and Lin, Yunhua and Wei, Gejin and Meng, Fake and Li, Shanhang and Yang, Mingxiu and Ning, Binyuan and Deng, Jingxin and Xiong, Liang and Hu, Jianming and Liu, Yun and Wei, Qingjun},
title = {Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing},
journal = {PLOS Computational Biology},
year = {2026},
volume = {22},
number = {11},
pages = {e1014828},
doi = {10.1371/journal.pcbi.1014828}
}
EUVIMED